NCT04178798View on ClinicalTrials.gov

Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia

PHASE3CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 9, 2019

Primary Completion Date

December 3, 2024

Study Completion Date

December 3, 2024

Conditions
Chronic Lymphocytic Leukemia- Binet Staging System
Interventions
DRUG

Acalabrutinib 100 MG Oral Capsule

Patients in Arm A will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos Schedule.

Trial Locations (8)

29603

Hospital Costa del Sol, Marbella

37007

Hospital Universitario Salamanca, Salamanca

39009

Hospital Universitario Marqués de Valdecilla, Santander

41014

Hospital Universitario Virgen de Valme, Seville

45004

Hospital Virgen de la Salud (Complejo Hospitalario de Toledo), Toledo

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona

08908

ICO L´Hospitalet - Hospital Duran i Reynals, Barcelona

All Listed Sponsors
lead

PETHEMA Foundation

OTHER

NCT04178798 - Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter